Two types of engineered T cells have been successfully used to treat cancer patients, one with an antigen recognition domain derived from antibodies (chimeric antigen receptors, CARs) and the other derived from T-cell receptors (TCRs). CARs employ high-affinity antigen binding domains and co-stimula...
ORGANISM(S): Homo sapiens